FibroGen (NASDAQ:FGEN) Issues Quarterly Earnings Results

FibroGen (NASDAQ:FGEN) posted its earnings results on Monday. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.02, Briefing.com reports. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The business had revenue of $33.17 million during the quarter, compared to analyst estimates of $31.61 million. During the same quarter last year, the firm earned ($0.50) earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year.

Shares of FGEN traded down $0.76 on Tuesday, hitting $34.64. The company’s stock had a trading volume of 26,941 shares, compared to its average volume of 810,108. The company has a market capitalization of $3.62 billion, a PE ratio of -33.86 and a beta of 1.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.73 and a quick ratio of 9.71. FibroGen has a fifty-two week low of $33.51 and a fifty-two week high of $61.23. The company has a 50 day moving average price of $38.61 and a 200 day moving average price of $41.88.

In related news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total value of $1,757,063.88. Following the completion of the transaction, the chief executive officer now owns 2,356,578 shares in the company, valued at approximately $104,467,102.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $36.58, for a total transaction of $205,762.50. Following the completion of the transaction, the senior vice president now owns 145,253 shares of the company’s stock, valued at approximately $5,313,354.74. The disclosure for this sale can be found here. Insiders sold a total of 86,756 shares of company stock worth $3,644,083 over the last three months. 7.83% of the stock is owned by company insiders.

FGEN has been the topic of a number of recent research reports. Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a report on Tuesday, August 13th. BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a report on Thursday, October 17th. ValuEngine raised FibroGen from a “hold” rating to a “buy” rating in a report on Friday. TheStreet raised FibroGen from a “d+” rating to a “c” rating in a report on Tuesday, August 13th. Finally, Mizuho reaffirmed a “positive” rating and set a $72.00 price objective (up from $65.00) on shares of FibroGen in a report on Monday. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $58.33.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Story: Cash Asset Ratio

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit